ROQAF
Price
$0.05
Change
-$0.00 (-0.00%)
Updated
Oct 3 closing price
Capitalization
3.96M
SVRA
Price
$2.69
Change
-$0.00 (-0.00%)
Updated
Feb 21 closing price
Capitalization
461.65M
18 days until earnings call
Ad is loading...

ROQAF vs SVRA

Header iconROQAF vs SVRA Comparison
Open Charts ROQAF vs SVRABanner chart's image
Roquefort Therapeutics
Price$0.05
Change-$0.00 (-0.00%)
Volume$600
Capitalization3.96M
Savara
Price$2.69
Change-$0.00 (-0.00%)
Volume$695.92K
Capitalization461.65M
ROQAF vs SVRA Comparison Chart
Loading...
SVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ROQAF vs. SVRA commentary
Feb 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ROQAF is a Buy and SVRA is a Hold.

Ad is loading...
COMPARISON
Comparison
Feb 23, 2025
Stock price -- (ROQAF: $0.05 vs. SVRA: $2.69)
Brand notoriety: ROQAF and SVRA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ROQAF: 100% vs. SVRA: 80%
Market capitalization -- ROQAF: $3.96M vs. SVRA: $461.65M
ROQAF [@Biotechnology] is valued at $3.96M. SVRA’s [@Biotechnology] market capitalization is $461.65M. The market cap for tickers in the [@Biotechnology] industry ranges from $393.7B to $0. The average market capitalization across the [@Biotechnology] industry is $2.51B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ROQAF’s FA Score shows that 1 FA rating(s) are green whileSVRA’s FA Score has 0 green FA rating(s).

  • ROQAF’s FA Score: 1 green, 4 red.
  • SVRA’s FA Score: 0 green, 5 red.
According to our system of comparison, ROQAF is a better buy in the long-term than SVRA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SVRA’s TA Score shows that 3 TA indicator(s) are bullish.

  • SVRA’s TA Score: 3 bullish, 4 bearish.

Price Growth

ROQAF (@Biotechnology) experienced а 0.00% price change this week, while SVRA (@Biotechnology) price change was -4.61% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.71%. For the same industry, the average monthly price growth was -2.01%, and the average quarterly price growth was +0.86%.

Reported Earning Dates

SVRA is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (-1.71% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SVRA($462M) has a higher market cap than ROQAF($3.96M). ROQAF YTD gains are higher at: 0.000 vs. SVRA (-12.378).
ROQAFSVRAROQAF / SVRA
Capitalization3.96M462M1%
EBITDAN/A-88.58M-
Gain YTD0.000-12.378-
P/E RatioN/AN/A-
RevenueN/A0-
Total CashN/A219M-
Total DebtN/A26.7M-
FUNDAMENTALS RATINGS
SVRA: Fundamental Ratings
SVRA
OUTLOOK RATING
1..100
10
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
85
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
SVRA
RSI
ODDS (%)
Bullish Trend 6 days ago
85%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
88%
Momentum
ODDS (%)
Bearish Trend 3 days ago
83%
MACD
ODDS (%)
Bullish Trend 3 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
84%
Advances
ODDS (%)
Bullish Trend 20 days ago
81%
Declines
ODDS (%)
Bearish Trend 3 days ago
86%
BollingerBands
ODDS (%)
N/A
Aroon
ODDS (%)
Bearish Trend 3 days ago
78%
View a ticker or compare two or three
Ad is loading...
SVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RMYCX9.34-0.02
-0.21%
Russell Inv Multi-Strategy Income C
PLBBX37.05-0.26
-0.70%
Plumb Balanced Investor
EQTKX16.38-0.25
-1.50%
Shelton Equity Income Class K
VHIAX38.19-0.99
-2.53%
JPMorgan Growth Advantage A
ACRNX11.95-0.51
-4.09%
Columbia Acorn Inst

ROQAF and

Correlation & Price change

A.I.dvisor indicates that over the last year, ROQAF has been loosely correlated with GNTA. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if ROQAF jumps, then GNTA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ROQAF
1D Price
Change %
ROQAF100%
N/A
GNTA - ROQAF
36%
Loosely correlated
+0.51%
ATXI - ROQAF
26%
Poorly correlated
-2.86%
CRBP - ROQAF
22%
Poorly correlated
-1.21%
SVRA - ROQAF
21%
Poorly correlated
N/A
SKYE - ROQAF
21%
Poorly correlated
-4.79%
More

SVRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, SVRA has been loosely correlated with LRMR. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if SVRA jumps, then LRMR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SVRA
1D Price
Change %
SVRA100%
N/A
LRMR - SVRA
43%
Loosely correlated
-2.45%
KYMR - SVRA
41%
Loosely correlated
-1.63%
ATXS - SVRA
40%
Loosely correlated
-0.15%
SLNO - SVRA
40%
Loosely correlated
-2.72%
IMNM - SVRA
38%
Loosely correlated
-5.84%
More